Progyny (PGNY) is back in focus for investors after a recent move in its share price, with the stock up about 19% over the past month and roughly 77% over the past 3 months.

Those recent gains sit alongside a 21.8% year to date share price return and a 33.6% total shareholder return over the past year, while the 3 year and 5 year total shareholder returns remain weak. This suggests recent momentum in Progyny may reflect a reassessment of its growth prospects and risks rather than a long run trend.

If Progyny’s recent swing has you thinking about where else growth could emerge, this is a good moment to scan a wider field of healthcare related AI opportunities using the 41 healthcare AI stocks

After Progyny’s sharp rebound and a share price now close to analyst targets, the next issue is whether the recently highlighted intrinsic discount still points to meaningful upside or if the bulk of the repricing has already played out.

Most Popular Narrative: 6% Overvalued

The most followed narrative currently pins Progyny’s fair value at $29.73, slightly below the last close at $31.35. This frames recent price strength in a more cautious light.

Sustained high levels of employer interest in women's health and family-building benefits, supported by a recent national study and 81% of HR leaders prioritizing these services, point toward robust long-term demand, especially as employers seek to attract and retain talent. This broadening acceptance and adoption are likely to expand revenue and topline growth over time.

Curious what sits behind that growth story and a fair value below the current share price? The narrative leans on detailed assumptions for revenue, margins, and future earnings power without spelling them out in the headline numbers.

Result: Fair Value of $29.73 (OVERVALUED)

However, Progyny’s story could shift quickly if employer cost cutting reduces demand for premium fertility benefits or if rising competition starts to pressure margins and client wins.

Another View on Progyny’s Valuation

While the analyst narrative suggests Progyny is about 6% overvalued around $31.35 versus a $29.73 fair value, the SWS DCF model points in a different direction, with an estimate of future cash flow value at $64.47. This indicates the stock is priced well below that level. Which model do you find more convincing?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Progyny for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Seeing mixed signals on Progyny and unsure which valuation view to lean on? Act while the information is fresh and review the 3 key rewards

Looking for more investment ideas beyond Progyny?

If Progyny has sharpened your focus on opportunities, do not stop here. Broaden your watchlist now so you are not late to the next move.

• Target stronger value potential by scanning companies that look mispriced on fundamentals using the 47 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks yielding solid payouts through the 7 dividend fortresses.
• Reduce portfolio stress by checking companies that score well on financial resilience with the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.